Literature DB >> 18989579

Nidus vespae protein inhibiting proliferation of HepG2 hepatoma cells through extracellular signal-regulated kinase signaling pathways and inducing G1 cell cycle arrest.

Changdong Wang1, Peng Chen, Hongjuan Jin, Xu Yan, Lu Gan, Yi Li, Shiyi Zhou, Junli Chang, Yuesheng Wang, Guangxiao Yang, Guangyuan He.   

Abstract

A protein named NVP(1) was isolated from Nidus vespae. The aim of the present study was to elucidate whether and how NVP(1) modulates the proliferation of HepG2 cells. NVP(1) at a concentration of 6.6 microg/ml could arrest the cell cycle at stage G1 and inhibit the mRNA expression of cyclinB, cyclinD1 and cyclinE. NVP(1) suppressed cdk2 protein expression, but increased p27 and p21 protein expression. However, NVP(1) did not alter p16 protein expression levels. NVP(1) promoted apoptosis in HepG2 cells as indicated by nuclear chromatin condensation, and in addition, the extracellular signal-regulated kinase (ERK) signaling pathway was activated. Moreover, the p-ERK protein expression level was attenuated when the HepG2 cells were pretreated with ERK inhibitor PD98059. These results demonstrate that NVP(1) inhibits proliferation of HepG2 through ERK signaling pathway. NVP(1) could be a potential drug for liver cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18989579     DOI: 10.1111/j.1745-7270.2008.00476.x

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  3 in total

1.  MicroRNA‑23a‑5p mediates the proliferation and differentiation of C2C12 myoblasts.

Authors:  Xue Zhao; Hao Gu; Linghui Wang; Peiwen Zhang; Jingjing Du; Linyuan Shen; Dongmei Jiang; Jinyong Wang; Xuewei Li; Shunhua Zhang; Mingzhou Li; Li Zhu
Journal:  Mol Med Rep       Date:  2020-09-02       Impact factor: 2.952

2.  Preliminary Study on the In Vitro Antitumor Effects of Nidus Vespae on Gastric Cancer.

Authors:  Ming Zhu; Weiwei Han; Yang Ling; Qiufeng Qi; Yaping Zhang; Yun Peng; Lin Chen; Yanqing Bao; Yongping Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-07       Impact factor: 2.629

Review 3.  Venom-based peptide therapy: insights into anti-cancer mechanism.

Authors:  Rui Ma; Ravikiran Mahadevappa; Hang Fai Kwok
Journal:  Oncotarget       Date:  2017-10-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.